^
Association details:
| Biomarker: | MYC translocation + BCL6 translocation + BCL2 translocation |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Regimen: | (Rituxan (rituximab) + cyclophosphamide + doxorubicin hydrochloride + prednisone + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3762 Long-term outcomes for stage I-II diffuse large B-cell lymphoma treated with rituximab and chemotherapy with or without radiotherapy
Published date:
11/01/2020
Excerpt:
Seven cases were reclassified as high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 (double/triple hit). 113 patients (62.8%) received rituximab-chemotherapy (median 5 cycles, IQR = 4-6 with R-CHOP for n = 92 [81.4%]) followed by RT...There was a significantly higher 8-year PFS, 79.9% vs. 58.2% (P<0.0001), and OS, 87.5 vs. 67.9% (P<0.0001), for mIPI 0-1 vs. mIPI >1, respectively....PFS and OS for patients with stage I-II DLBCL were excellent following rituximab-chemotherapy with or without RT for those who were low risk (mIPI 0-1).
